Abcam, ab185039-100µL, Alexa Fluor® 488 Anti-EEA1 antibody [EPR4245] - Early Endosome Marker

Product details
Patented technology Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on recombinant antibodies.

Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
EEA1 plays a significant role in early endosomal pathways facilitating endocytic vesicle fusion. EEA1 does not usually work alone; it functions as part of a larger complex involving other endosomal proteins. This protein acts as a tethering molecule which stabilizes the interaction of vesicles with endosomes. By anchoring vesicles EEA1 ensures the correct delivery and sorting of cargo within the cell which is important for cellular homeostasis and signaling.
Pathways
EEA1 contributes to the endocytic pathway and receptor recycling. It ensures proper functioning of the endocytic recycling of receptors such as the epidermal growth factor receptor (EGFR). EEA1-mediated tethering is vital for these pathways and it works closely with proteins like Rab5 which regulate endocytic trafficking. Through these interactions EEA1 affects cellular processes by controlling the flow of signaling receptors and other molecules within the cell.